Eye, hepatobiliary, and renal disorders of erlotinib in patients with non-small-cell lung cancer: A meta-analysis

BACKGROUND: Erlotinib is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors used to treat EGFR mutation positive non-small-cell lung cancer (NSCLC). Skin rash and diarrhea are well-known and common adverse events in patients receiving erlotinib, whereas other adverse events, inclu...

Descripción completa

Detalles Bibliográficos
Autores principales: Choi, Hye Duck, Chang, Min Jung
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7360022/
https://www.ncbi.nlm.nih.gov/pubmed/32663210
http://dx.doi.org/10.1371/journal.pone.0234818

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7360022/
https://www.ncbi.nlm.nih.gov/pubmed/32663210
http://dx.doi.org/10.1371/journal.pone.0234818

Ejemplares similares